Skip to Content

Eculizumab Disease Interactions

There are 5 disease interactions with eculizumab:


Immunosuppressive Agents (Includes Eculizumab) ↔ Infections

Severe Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.


Immunosuppressive Agents (Includes Eculizumab) ↔ Pml

Severe Potential Hazard, Moderate plausibility

Applies to: Immunodeficiency

Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.


Eculizumab (Includes Eculizumab) ↔ Meningococcal Infections

Moderate Potential Hazard, Moderate plausibility

Applies to: Infectious Diarrhea/Enterocolitis/Gastroenteritis

Eculizumab is contraindicated in patients with unresolved serious Neisseria meningitidis infection, in those who are not currently vaccinated against Neisseria meningitidis, unless the risks of delaying treatment outweigh the risks of developing a meningococcal infection. Life-threatening and fatal meningococcal infections have occurred in patients treated with eculizumab. The use of eculizumab increases a patient's susceptibility to serious meningococcal infections (septicemia and/or meningitis). Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if an infection is suspected. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. It is recommended to discontinue eculizumab in patients who are undergoing treatment for serious meningococcal infections.


Eculizumab (Includes Eculizumab) ↔ Thrombotic Microangiopathy

Moderate Potential Hazard, Moderate plausibility

Applies to: History - Thrombotic/Thromboembolic Disorder

Thrombotic microangiopathy (TMA) complications have occurred after treatment discontinuation or after a missed dose of eculizumab. It is recommended to monitor patients with atypical hemolytic uremic syndrome for signs and symptoms of thrombotic microangiopathy (TMA) complications for at least 12 weeks. If TMA complications occur after eculizumab discontinuation, consider reinstitution of treatment, plasma therapy or appropriate organ-specific supportive measures.


Eculizumab (Includes Eculizumab) ↔ Vaccination

Moderate Potential Hazard, Moderate plausibility

Applies to: Immunodeficiency, Neutropenia

Eculizumab blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria. Caution is advised when using this agent in immunocompromised and neutropenic patients as Aspergillus infections may occur. It is recommended to administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenza type b (Hib) infections according to the Advisory Committee on Immunization Practices (ACIP) guidelines and to use caution when administering to patients with any systemic infection.

eculizumab drug Interactions

There are 17 drug interactions with eculizumab

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.